Suraksha Diagnostic IPO
Company Profile
Incorporation: 2005
Business Focus: Integrated diagnostic services specializing in pathology, radiology, and medical consultations in East India.
Operational Footprint: Predominantly in West Bengal, Bihar, Assam, and Meghalaya.
Key Highlights
Infrastructure: Central reference laboratory supported by 8 satellite labs, 49 diagnostic centres, and 166 sample collection centres (as of June 30, 2024).
Customer Touchpoints: 215 locations offering online and offline consultations.
Polyclinic Network: 120 polyclinics with over 750 medical professionals under 44 diagnostic centres.
Technology Integration:
Laboratory Information Management System (LIMS)
Radiology Information System (RIS)
Picture Archive Communication System (PACS)
Enterprise Resource Planning System (ERP)
Service Offerings
Diagnostic Services: Comprehensive pathology and radiology tests.
Vaccination Services: Catering to preventive healthcare needs.
Customized Testing Packages: Focus on disease prediction and early detection.
Advanced Technology: Digital pathology and AI-based blood test generation, along with a digital radiology platform for quicker reporting.
Strengths
Market Leadership: Leading presence in East India’s diagnostic market, tapping into the growth potential of a fragmented industry.
Comprehensive Services: Integrated pathology, radiology, and consultation offerings under one roof.
Technological Edge: Use of advanced infrastructure and platforms for streamlined operations.
Quality Accreditation: Recognized by the College of American Pathologists and NABL.
Trusted Brand: Strong consumer base supported by a focus on quality and skilled personnel.
Risks
Geographical Concentration: Heavy reliance on West Bengal; any adverse developments in this region could significantly impact the business.
Technological Advancements: Falling behind in adopting new tests and technology could erode the competitive edge.
Third-Party Dependencies: Reliance on vendors for testing equipment and supply chain disruptions pose operational risks.
Franchise Model: Many collection centres are franchisee-operated, and any failure to meet quality standards could damage the brand’s reputation.
Intense Competition: High competition in the diagnostics industry could lead to price pressures, impacting profitability.
Debt Levels: Significant financial liabilities may restrict operational flexibility and affect financial health.
Suraksha Diagnostic IPO: Key Details
IPO Dates: 29 to 3 December, 2024
Price Band: ₹420 to ₹441 per share
Lot Size: 34 shares
Total Issue Size: ₹846.25 crore
Retail Quota: 35%
GMP: Nil (only for info)
DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matters published here are purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on the information published here. Any reader making decisions based on any information published here does so entirely at their own risk. Investors should bear in mind that any investment in the stock market is subject to unpredictable market-related risks. The author has no plans to invest in this offer and also the author does not recommend investing in any offer published on this website.